Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Apr 9 2010

XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

The poster, entitled "A novel humanized anti-IL-1beta antibody is highly effective at inhibiting IL-1 induced IL-6 production in myeloma patients in vitro" will be presented on Monday, April 19 at 2:00 PM Eastern. The abstract upon which the poster is based is now available on the conference Web site: www.aacr.org.

Source:

http://www.xoma.com/

Posted in: Drug Trial News | Medical Science News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Study reveals waning antibody response to monkeypox vaccine over time
Antibody discovery could explain mysteries about COVID-19 and long COVID
Study shows potential for universal flu vaccine with broad antibody response
COVID-19 booster enhances virus neutralizing antibodies in breast milk, new study reveals
Therapeutic potential of CD20 x CD3 bispecific antibodies
Study reveals why COVID-19 antibodies fade quickly
Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration
Researchers receive NIH grant to help develop gene therapy for HIV

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Research unveils bispecific antibodies for B-cell lymphoma treatment